Aldevron Breakthrough Blog

Presentation: Trade-offs in RNA Manufacturing

November 19, 2025 by Aldevron

Balancing Yield and Full-Length Product

In mRNA manufacturing, two critical metrics—yield and percent full-length product (FLP)—often sit at opposite ends of the optimization spectrum. While high yield ensures sufficient product quantity, FLP reflects the purity and integrity of the RNA, which is essential for therapeutic efficacy and regulatory compliance.

In her presentation, Trade-offs between yield and full-length product in RNA manufacturing, Rebecca Young, PhD, senior scientist for R&D at Aldevron, discusses the relationship between yield and FLP and how they can shift, whether comparing conditions within a single construct or across multiple constructs.

High points of Young’s presentation, delivered at the 2025 mRNA Process Development and Manufacturing Summit, focus on several variables that must be balanced to optimize both quantity and quality, including:

Young provides insight into the goal of achieving sufficient yield without sacrificing product integrity, all while understanding and managing the trade-offs between yield and FLP to develop scalable, cost-effective, and high-quality mRNA therapeutics.

Watch the Presentation Now

Watch the Presentation Now

Subscribe to our blog

ABOUT THE AUTHOR

Aldevron

Aldevron is a premier manufacturing partner, producing high-quality plasmid DNA, mRNA, proteins, and other key components for the development of vaccines, gene and cell therapies, immunotherapies and other treatments. As a part of the Danaher Corporation family of global science and technology companies, Aldevron supports thousands of scientists who are developing revolutionary, lifesaving treatments for millions of people. You can follow the company on LinkedIn, Facebook and YouTube.